Brandywine Global Investment Management LLC Sells 10,534 Shares of Cencora, Inc. (NYSE:COR)

Brandywine Global Investment Management LLC lowered its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 7.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 127,717 shares of the company's stock after selling 10,534 shares during the quarter. Brandywine Global Investment Management LLC owned approximately 0.07% of Cencora worth $28,695,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. JFS Wealth Advisors LLC lifted its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC raised its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Kentucky Trust Co purchased a new position in shares of Cencora in the 4th quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co boosted its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the subject of a number of research reports. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Remove Ads

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock valued at $8,034,778 over the last ninety days. Insiders own 10.80% of the company's stock.

Cencora Stock Down 3.5 %

Shares of NYSE COR traded down $10.07 during midday trading on Friday, hitting $279.29. The stock had a trading volume of 4,404,535 shares, compared to its average volume of 1,469,415. The business's 50 day moving average is $257.28 and its 200-day moving average is $242.65. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $54.16 billion, a P/E ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.